ScholarIQanswers from OpenAlex
Kishiwada City Hospital
InstitutionResearch output, impact & collaborations
Kishiwada City Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Kishiwada City Hospital?
ScholarIQrecord summary
Kishiwada City Hospital is a research organisation in Osaka, JP. OpenAlex records 1,033 works and 33,341 citations for it. 273 researchers list it as their most recent affiliation.
How many works does Kishiwada City Hospital have?
ScholarIQindexed works
Kishiwada City Hospital has 1,033 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kishiwada City Hospital have?
ScholarIQcitation count
Kishiwada City Hospital has 33,341 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Kishiwada City Hospital?
ScholarIQresearcher count
Kishiwada City Hospital has 273 researchers in the ScholarIQ index.
What is the average h-index at Kishiwada City Hospital?
ScholarIQavg h-index
Kishiwada City Hospital has an average h-index of 13.5 in OpenAlex.
What is the ROR of Kishiwada City Hospital?
ScholarIQror
The ROR for Kishiwada City Hospital is on the source record.
What is the OpenAlex record for Kishiwada City Hospital?
ScholarIQopenalex
The OpenAlex for Kishiwada City Hospital is on the source record.
Who are the most-cited researchers behind Kishiwada City Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Kishiwada City Hospital?
ScholarIQmost cited works
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Narikazu Boku, Min‐Hee Ryu, Ken Kato, Hyun Cheol Chung, Keiko Minashi, K.-W. Lee, H. Cho, Won Ki Kang, Yoshito Komatsu, Masahiro Tsuda, Kensei Yamaguchi, Hiroki Hara, Soichi Fumita, Mizutomo Azuma, L.-T. Chen, Yoon‐Koo Kang
An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
Kimio Yonesaka, Naoki Takegawa, Satomi Watanabe, Koji Haratani, Hisato Kawakami, Kazuko Sakai, Yasutaka Chiba, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani, Kazuto Nishio, Kazuhiko Nakagawa
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors
Masayuki Takeda, Takayuki Takahama, Kazuko Sakai, Shigeki Shimizu, Satomi Watanabe, Hisato Kawakami, Kaoru Tanaka, Chihiro Sato, Hidetoshi Hayashi, Yoshikane Nonagase, Kimio Yonesaka, Naoki Takegawa, Tatsuya Okuno, Takeshi Yoshida, Soichi Fumita, Shinichiro Suzuki, Koji Haratani, Kazumasa Saigoh, Akihiko Ito, Tetsuya Mitsudomi, Hisashi Handa, Kazuya Fukuoka, Kazuhiko Nakagawa, Kazuto Nishio
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa
HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
Naoki Takegawa, Kimio Yonesaka, Kazuko Sakai, Hiroto Ueda, Satomi Watanabe, Yoshikane Nonagase, Tatsuya Okuno, Masayuki Takeda, Osamu Maenishi, Junji Tsurutani, Taroh Satoh, Isamu Okamoto, Kazuto Nishio, Takao Tamura, Kazuhiko Nakagawa
How much of the research on Kishiwada City Hospital is open access?
ScholarIQopen access share
58%OPEN ACCESS